Mölnlycke Health Care and Transdiagen announce research collaboration to drive innovation in wound care

GOTHEMBURG, Sweden, Oct. 24, 2024 /PRNewswire/ — Today, Mölnlycke Health Care, a leading global MedTech company specializing in wound care and wound management, announces a research collaboration with Transdiagen (TDG), a precision medicine company developing drugs and diagnostics for the chronic wound healing and tissue regeneration. The collaboration aims to use TDG’s new wound gene signatures to further explore Mölnlycke’s products.

Emma Wright, EVP Medical Director at Mölnlycke, commented: “We are excited about our research collaboration with TDG which allows us to be at the forefront of advancing the understanding of chronic wounds. This opens up a wealth of opportunities for future innovation in under-resourced sectors and under the priority area of ​​wound care.”

James Harding, CEO of Transdiagen, added: “We are delighted to be working with Mölnlycke on this R&D programme. This collaboration will enable Mölnlycke to access the new TDG models to generate functional insights into the mode of action of innovative, biologic wound treatment solutions. We believe this marks a new chapter in the data-driven, evidence-based approach to the treatment of complex wounds.”

The collaboration will start shortly.

For more information, please contact:

Jennifer Doak

Director of Global Communications Wound care
Email: [email protected]

Phone: +1 678 206 6179

This information is brought to you by Cision http://news.cision.com

https://news.cision.com/molnlycke/r/molnlycke–health-care-and-transdiagen-announce-research-collaboration-to-drive-innovation-in-wound-,c4056056

The following files are available for download:

See original content: https://www.prnewswire.co.uk/news-releases/molnlycke-health-care-and-transdiagen-announce-research-collaboration-to-drive-innovation-in-wound-care-302286130. html